MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-08-2022
ChemoCentryx Current Ratio 2011-2026 | CCXI
Annual Current Ratio ChemoCentryx
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.05 | 8.56 | 2.95 | 2.82 | 5.46 | 3.88 | 13.1 | 9.08 | 19.5 | 9.25 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.5 | 2.82 | 7.77 |
Quarterly Current Ratio ChemoCentryx
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.29 | 2.42 | 3.05 | 3.27 | 3.4 | 3.61 | 3.89 | 3.89 | 3.89 | 3.89 | 1.46 | 1.46 | 1.46 | 1.46 | 1.09 | 1.09 | 1.09 | 1.09 | 1.72 | 1.72 | 1.72 | 1.72 | 1.47 | 1.47 | 1.47 | 1.47 | 13.8 | 13.8 | 13.8 | 13.8 | 14 | 14 | 14 | 14 | 21.4 | 21.4 | 21.4 | 21.4 | 10.2 | 10.2 | 10.2 | 10.2 | 3.97 | 3.97 | 3.97 | 3.97 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.4 | 1.09 | 6.74 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
Celldex Therapeutics
CLDX
|
10.4 | $ 34.99 | 3.35 % | $ 2.32 B |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
7.02 | $ 4.36 | 9.92 % | $ 10.5 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | USA |
 |
Akouos
AKUS
|
6.18 | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
2.84 | - | 4.14 % | $ 49.1 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
2.74 | $ 0.88 | 2.99 % | $ 5.92 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
2.45 | $ 5.52 | 7.71 % | $ 372 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
2.53 | $ 6.66 | -13.05 % | $ 65.8 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.19 | $ 309.33 | -3.37 % | $ 40.5 B | USA |
 |
Allakos
ALLK
|
3.26 | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
2.68 | - | -18.52 % | $ 27.3 M | Britain |
 |
Forte Biosciences
FBRX
|
3.8 | $ 32.91 | 4.71 % | $ 426 M | USA |
|
Applied Molecular Transport
AMTI
|
2.31 | - | - | $ 10.1 M | USA |
 |
Galectin Therapeutics
GALT
|
0.134 | $ 2.47 | 9.29 % | $ 158 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.94 | $ 22.62 | 3.71 % | $ 1.06 B | USA |
 |
Applied Therapeutics
APLT
|
0.762 | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
7.95 | $ 104.72 | 2.55 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
2.35 | - | -39.0 % | $ 4.57 M | USA |
 |
Galapagos NV
GLPG
|
20 | $ 29.25 | 1.35 % | $ 2.69 B |  Belgium |
 |
Aravive
ARAV
|
1.21 | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
1.67 | $ 8.73 | 1.54 % | $ 6.83 B |  Spain |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | USA |
 |
GT Biopharma
GTBP
|
6.14 | $ 0.38 | -3.91 % | $ 2.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 3.04 | -1.3 % | $ 5 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
1.22 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
0.995 | - | -10.17 % | $ 12.2 K | USA |
 |
BioXcel Therapeutics
BTAI
|
0.32 | $ 1.19 | 10.75 % | $ 14.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
Hoth Therapeutics
HOTH
|
5.23 | $ 0.72 | -3.12 % | $ 9.94 M | USA |
 |
Akebia Therapeutics
AKBA
|
1.09 | $ 1.44 | 6.65 % | $ 370 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
3.17 | $ 30.25 | 2.82 % | $ 1.74 B | USA |
 |
Aquestive Therapeutics
AQST
|
0.827 | $ 4.37 | 2.58 % | $ 467 M | USA |
 |
InflaRx N.V.
IFRX
|
4.04 | $ 1.56 | 29.91 % | $ 152 M | Germany |
 |
AstraZeneca PLC
AZN
|
1.75 | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
1.78 | $ 24.77 | 2.4 % | $ 3.15 B | USA |
 |
Burford Capital Limited
BUR
|
2.14 | $ 4.97 | 6.32 % | $ 792 M | Britain |
 |
AIkido Pharma
AIKI
|
2.59 | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
0.0929 | - | -2.5 % | $ 5.88 M | USA |
 |
Immutep Limited
IMMP
|
11.8 | $ 0.59 | 1.79 % | $ 1.08 B | Australia |
 |
BioDelivery Sciences International
BDSI
|
2.37 | - | -4.8 % | $ 255 M | USA |
 |
Cabaletta Bio
CABA
|
3.11 | $ 3.41 | -3.12 % | $ 343 M | USA |